{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0114","upperLimit":"0.0225","value":"0.0154"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"261"}],"units":"Participants"}],"description":"The reported cross-arm CL/F value is a fixed-effect parameter determined from a population PK analysis. The analysis included pooled data from participants enrolled in multiple studies including those who were not enrolled in this study. The NCTID include: NCT01719380, NCT01543698, and NCT01436656. An additional study ARRAY-162-105 is not required to register.","dispersionType":"95% Confidence Interval","groups":[{"description":"Encorafenib + binimetinib + cetuximab. Encorafenib + cetuximab. Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.","id":"OG000","title":"Pharmacokinetic Population of Encorafenib"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The analysis set included all participants in the PK set with measurable plasma concentrations of the test drug plus concentrations from subjects from 4 additional clinical studies. Participants were analyzed according to the actual treatment and dose received.","reportingStatus":"POSTED","timeFrame":"2 and 6 hours post-dose on Day 1 of Cycle 1, Predose and 2 hours post-dose on Day 1 of Cycle 2 (each cycle of 28 days)","title":"(Phase 3) Evaluation of the Model-Based Clearance (CL) for Cetuximab","type":"SECONDARY","unitOfMeasure":"Liter/hour"}